NCT07688720 Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause
| NCT ID | NCT07688720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Texas Christian University |
| Condition | Perimenopause |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-06 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2026-06 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Transcutaneous Auricular Neurostimulation (tAN) will be administered to women with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and perimenopause. The investigators will examine whether tAN improves symptomology by collecting self-report data before the intervention, during the intervention, and following the intervention.
Eligibility Criteria
PMS/PMDD Study: Inclusion Criteria: * Assigned female at birth * Age 18 to 45 * Naturally cycling * Regularly occurring menstrual cycle * Must identify as having PMS or PMDD * Reliable ability to complete online study surveys Exclusion Criteria: * Using hormonal birth control * Pregnant or lactating/breastfeeding * History of seizures * Implanted devices * Current or previous diagnosis of any heart conditions * Abnormal ear anatomy * Non-removable piercings on the ear * Recent ear infection * Taking SSRIs * Taking steroids * Taking hormone therapy * If the participant anticipates starting or stopping prescription medications during the study period * Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.) * Participant has a history traumatic brain injury within the past 12 months * Must not have any other mental illness or mood disorder Perimenopause Study: Inclusion Criteria: * Assigned female at birth. * Age 40 to 55 * Must have newly variable menstrual cycles or report identifying as perimenopausal * Reliable ability to complete online study surveys Exclusion Criteria: * Using hormonal birth control * Pregnant or lactating/breastfeeding * History of seizures * Implanted devices * Current or previous diagnosis of any heart conditions * Abnormal ear anatomy * Non-removable piercings on the ear * Recent ear infection * Taking SSRIs * Taking steroids * Taking hormone therapy * If the participant anticipates starting or stopping prescription medications during the study period. * Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.) * Participant has a history traumatic brain injury within the past 12 months * have a hysterectomy In both studies we will confirm that participants are symptomatic shortly following enrollment.
Contact & Investigator
Sarah E Hill, PhD
PRINCIPAL INVESTIGATOR
Texas Christian University
Frequently Asked Questions
Who can join the NCT07688720 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Perimenopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07688720 currently recruiting?
Yes, NCT07688720 is actively recruiting participants. Contact the research team at s.e.hill@tcu.edu for enrollment information.
Where is the NCT07688720 trial being conducted?
This trial is being conducted at Fort Worth, United States.
Who is sponsoring the NCT07688720 clinical trial?
NCT07688720 is sponsored by Texas Christian University. The principal investigator is Sarah E Hill, PhD at Texas Christian University. The trial plans to enroll 20 participants.